丙咪嗪,临床注释-2,变异和临床注释数据

丙咪嗪

临床注释ID

1183616940

药物名称(英)

imipramine

变异单倍型

CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5

基因

CYP2D6

证据级别

水平覆盖

水平修饰符

Tier 1 VIP

表现型类别(英)

Metabolism/PK

表现型类别

代谢/PK

分数

205.8125

PMID计数

计数的证据

表现型

抑郁症，重度；精神障碍

表现型(英)

Depressive Disorder, Major;Mental Disorders

最新日期

2021/4/23 0:00:00

URL

https://www.pharmgkb.org/clinicalAnnotation/1183616940

专业人口(英)

专业人口

临床等位基因

id	等位基因	注释文本
1220	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2D61 allele in combination with alleles that result in a normal metabolizer phenotype may have increased metabolism of imipramine as compared to patients with a no function allele in combination with a decreased or normal function allele or two no or decreased function alleles. Patients carrying the CYP2D61 allele in combination with alleles that result in a normal metabolizer phenotype may have decreased metabolism of imipramine as compared to patients with an increased function allele in combination with an increased or normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the CYP2D61 allele in combination with alleles that result in a normal metabolizer phenotype may also have decreased metabolism of imipramine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.
909	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D65 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D65 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D65 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.
908	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D64 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D64 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D64 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.
907	*3	The CYP2D63 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2D63 allele in combination with a no, decreased or normal function allele may have decreased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the CYP2D63 allele in combination with an increased function allele with an activity value of 3 or greater may have increased metabolism of imipramine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the CYP2D63 allele in combination with an increased function allele with an activity value of 2 may have similar metabolism of imipramine as compared to patients with other alleles that result in a normal metabolizer phenotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP2D6 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.

临床证据

id	证据的ID	总结
3439	1446902165	CYP2D6 4/4 + 4/5 (assigned as poor metabolizers phenotype) is associated with increased concentrations of desipramine and imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.
3438	1446900845	CYP2D6 3/5 + 3/4 + 4/4 + 4/5 (assigned as poor metabolizers phenotype) are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 1/1 + 1/5 + 1/3 + 1/4.
3437	1183684336	CYP2D6 3/4 + 4/4 + 5/5 are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 1/1 + 1/3 + 1/4.
3436	1183684359	CYP2D6 poor metabolizers are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.
3435	1446905104	CYP2D6 poor metabolizers are not associated with metabolism of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.
3434	1184470658	CYP2D6 poor metabolizers are associated with increased plasma concentration of imipramine and desipramine when treated with imipramine.
3433	1183684376	CYP2D6 poor metabolizers is associated with increased imipramine and desipramine plasma concentrations when treated with imipramine in people with Depressive Disorder, Major as compared to CYP2D6 normal metabolizers.
3432	1183684371	CYP2D6 poor metabolizers is associated with increased mean area under the plasma concentration-time curve (AUC) of desipramine when treated with imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.
3431	1183684300	CYP2D6 poor metabolizers is associated with increased antidepressant serum levels when treated with amitriptyline, clomipramine, doxepin, imipramine or trimipramine in people with Mental Disorders as compared to CYP2D6 normal metabolizers.
3430	1183682179	CYP2D6 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2D6 normal metabolizers.
3429	PA166104972	Annotation of DPWG Guideline for imipramine and CYP2D6
3428	PA166104999	Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6

临床病史

id	类型	评论
614	Update	Added DPWG guideline as evidence
613	Update	CA score added as part of scoring system release. LOE assigned following curator review.
612	Update	changed to allele description and PK evidence only
611	Update

最新招商产品更多>>